GeoVax has ‘timely and critical’ Mpox solution, says D. Boral Capital

D. Boral Capital says GeoVax Labs (GOVX)’ GEO-MVA vaccine, designed to target both Clade 1 and Clade 2 strains of Mpox, “presents a timely and critical solution to address this global health threat.” The Mpox epidemic, specifically driven by the newly emerging Clade 1b strain, continues to pose a significant health threat, the analyst tells investors in a research note. D. Boral believes the GEO-MVA vaccine offers a scalable and cost-effective alternative to current vaccines. As the governments talk with GeoVax, this program could rise in importance, the firm contends. It keeps a Buy rating on the shares with an $18 price target